Drug intelligence / Profile preview

BEN-101

Development stage: Phase 1
Lead developer: Bennu Biotherapeutics
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BEN-101 is an autologous tumor infiltrating lymphocyte (TIL) therapy being developed for the treatment of advanced solid tumors. It works through immunologic cytotoxicity and T lymphocyte replacements, using the patient's own immune cells to target cancer. The therapy is administered as an infusion followed by IL-2 after a non-myeloablative lymphodepletion preparative regimen.

Targets

pMHC-II (Peptide-major histocompatibility complex class II complex)

Beyond the preview

Go deeper on BEN-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEN-101.

Explore the full profile